ArticleClinical and molecular hepatology2021

Negligible risks of hepatocellular carcinoma during biomarker-defined immune-tolerant phase for patients with chronic hepatitis B.

Mi Young Jeon et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.